These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2029213)

  • 1. Increased concentrations of soluble interleukin-2 receptor in the serum of patients with systemic sclerosis.
    Airò P; Bettinzioli M; Gorla R; Cattaneo R
    Ann Rheum Dis; 1991 Apr; 50(4):270-1. PubMed ID: 2029213
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum levels of soluble interleukin-2 receptor in systemic and circumscribed scleroderma.
    Zillikens D; Blum C; Dummer R; Hartmann AA; Burg G
    Dermatology; 1992; 184(3):233-4. PubMed ID: 1392125
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum levels of soluble interleukin-2 receptor--a possible index of disease prognosis in systemic sclerosis.
    Lis A; Brzezińska-Wcisło L; Rubisz-Brzezińska J; Kulawik I
    Clin Exp Dermatol; 1997 Jan; 22(1):60-1. PubMed ID: 9330064
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis.
    Majewski S; Wojas-Pelc A; Malejczyk M; Szymanska E; Jablonska S
    Acta Derm Venereol; 1999 May; 79(3):207-10. PubMed ID: 10384918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.
    Clements PJ; Peter JB; Agopian MS; Telian NS; Furst DE
    J Rheumatol; 1990 Jul; 17(7):908-10. PubMed ID: 2213757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of anti-Fc gamma R antibodies and different cytokines in sera from patients with systemic sclerosis.
    Szegedi A; Czirják L
    J Am Acad Dermatol; 1996 Jul; 35(1):134. PubMed ID: 8682952
    [No Abstract]   [Full Text] [Related]  

  • 7. Soluble CD8 antigen in systemic sclerosis.
    Famularo G; Giacomelli R; Sacchetti S; Danese C; Luciani AM; Perego MA; Tonietti G
    J Clin Lab Immunol; 1990 Jul; 32(3):109-12. PubMed ID: 1966946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
    Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW
    Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Soluble receptors of cytokines in sera of patients with systemic sclerosis--clinical correlation].
    Lis AD; Brzezińska-Wcisło LA
    Wiad Lek; 2003; 56(11-12):532-6. PubMed ID: 15058159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating interleukin 1 beta and soluble interleukin 2 receptor: evaluation as markers of disease activity in scleroderma.
    Patrick MR; Kirkham BW; Graham M; Harrision LC
    J Rheumatol; 1995 Apr; 22(4):654-8. PubMed ID: 7791158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
    Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
    Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis.
    Vlachoyiannopoulos PG; Tsifetaki N; Dimitriou I; Galaris D; Papiris SA; Moutsopoulos HM
    Ann Rheum Dis; 1996 Oct; 55(10):761-8. PubMed ID: 8984943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients.
    Dziankowska-Bartkowiak B; Zalewska A; Sysa-Jedrzejowska A
    Med Sci Monit; 2004 May; 10(5):CR202-8. PubMed ID: 15114270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis.
    Kiener H; Graninger W; Machold K; Aringer M; Graninger WB
    Clin Exp Rheumatol; 1994; 12(5):483-7. PubMed ID: 7842528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease.
    La Montagna G; D'Angelo S; Valentini G
    J Rheumatol; 2003 Oct; 30(10):2147-51. PubMed ID: 14528508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cytokine and anti-Fc gamma R autoantibody measurements in patients with systemic sclerosis.
    Szegedi A; Czirják L; Unkeless JC; Boros P
    Acta Derm Venereol; 1996 Jan; 76(1):21-3. PubMed ID: 8721484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
    Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.
    Yanaba K; Takehara K; Sato S
    Ann Rheum Dis; 2004 May; 63(5):583-7. PubMed ID: 15082492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased serum IL-7 levels in patients with systemic sclerosis.
    Makino T; Fukushima S; Wakasugi S; Ihn H
    Clin Exp Rheumatol; 2009; 27(3 Suppl 54):68-9. PubMed ID: 19796566
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioactivity of prolactin in systemic sclerosis.
    La Montagna G; Meli R; Criscuolo T; D'Angelo S; Valentini G
    Clin Exp Rheumatol; 2004; 22(2):145-50. PubMed ID: 15083880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.